

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 September 2001 (27.09.2001)

PCT

(10) International Publication Number
WO 01/70740 A1

(51) International Patent Classification⁷: **C07D 457/04**

(21) International Application Number: **PCT/EP01/03099**

(22) International Filing Date: **19 March 2001 (19.03.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
0007308.0 24 March 2000 (24.03.2000) GB

(71) Applicant (*for all designated States except US*): **PHARMACIA & UPJOHN SPA [IT/IT]; Via Robert Koch, 1.2, I-20152 Milan (IT).**

(71) Applicants and

(72) Inventors: **TOMASI, Attilio [IT/IT]; Via Tommaso Gulli, 49, I-20147 Milan (IT). MAGENES, Stefania [IT/IT]; Via Oreglio, 8, I-20066 Melzo (IT). UNGARI, Mario [IT/IT]; Via Pietro Calvi, 10, I-20129 Milan (IT). RAMELLA, Giuliano [IT/IT]; P.le Europa, 1A, I-26019 Vailate (IT). PALLANZA, Gianfranco [IT/IT]; Via Savona, 94/A, I-20144 Milan (IT).**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/70740 A1

(54) Title: **PROCESS FOR PREPARING CRYSTALLINE FORM I OF CABERGOLINE**

(57) Abstract: A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals. A new solvate form V of cabergoline, useful as an intermediate, is also provided.

Process for preparing crystalline form I of cabergoline

The present invention concerns a new process for preparing crystalline Form I of cabergoline.

- 5 Cabergoline is an ergoline derivative interacting with D2 dopamine receptors and is endowed with different useful pharmaceutical activities and it is used in the treatment of hyperprolactinemia, central nervous system disorders (CNS) and other related diseases.
- 10 Cabergoline is the generic name of 1((6-allyl-ergolin-8 β -yl)-carbonyl)-1-(3-dimethylaminopropyl)-3-ethylurea, described and claimed in US 4,526,892. The synthesis of cabergoline molecule is reported also in Eur. J. Med. Chem., 24,421,(1989) and in GB-2,103,603-B. Crystalline cabergoline
- 15 Form I, an anhydrous not solvated form of cabergoline, was prepared by crystallization from diethyl ether, as described in Il Farmaco, 50 (3), 175-178 (1995).

- Cabergoline Form I, like cabergoline, displays a significant inhibitory effect with regard prolactin and has therapeutic
- 20 properties that make it possible to treat patients who have pathological conditions associated with an abnormal prolactin level, thus is useful in human and/or veterinary medicine. Cabergoline is also active, alone or in combination, in the treatment of reversible obstructive
- 25 airways diseases, for controlling intraocular pressure and for the treatment of glaucoma. It is also employed in the veterinary field, as antiprolactin agent and in cutting down drastically the proliferation of vertebrate animals. The several uses of cabergoline are for example described in
- 30 WO9948484, WO9936095, US5705510, WO9505176, EP040,325. Cabergoline Form I is particularly useful in the treatment of Parkinson's disease (PD), Restless Legs Syndrome (RLS), treatment of diseases like Progressive Supranuclear Palsy (PSP) and Multisystemic atrophy (MSA).
- 35 During our development work we discovered a new process for preparing crystalline Form I.

Thus, the present invention concerns a new process for preparing Form I of cabergoline and a new solvate Form V of cabergoline useful as intermediate.

Description of figures

- 5 Figure 1. XRD powder pattern of cabergoline Form I.
- Figure 2. DSC curve of cabergoline Form I.
- Figure 3. IR spectrum of cabergoline Form I (sample prepared by KBr powder technique).
- Figure 4. Solid state ^{13}C -NMR spectrum of cabergoline form I.
- 10 Figure 5. XRD powder pattern of cabergoline solvate Form V.
- Figure 6. DSC curve of cabergoline solvate Form V.
- Figure 7. IR spectrum of cabergoline solvate Form V (sample prepared by KBr powder technique).
- Figure 8. Solid state ^{13}C -NMR spectrum of cabergoline solvate
- 15 Form V.

Form I can be readily prepared according to the present invention starting from crude material by crystallization from a toluene/diethyl ether mixture, through a new solvate form V of cabergoline. The present process for preparing

20 Form I shows advantages with respect to the old one because of its greater reproducibility.

Characterisation

X-ray powder diffraction (XRD), differential scanning calorimetry (DSC), infrared (IR) spectroscopy and solid

25 state ^{13}C -NMR were used to characterise the new form.

X-Ray Powder Diffraction

Powder X-ray diffraction was performed using either a Scintag X1 or X2 Advanced Diffraction System operating under Scintag DMS/NT[®] Ver 1.30a and 1.36b respectively, and

30 Microsoft Windows NT 4.0[™] software. The system used a copper X-ray source maintained at 45 kV and 40 mA to provide $\text{CuK}\alpha_1$ emission of 1.5406 Angstroms and a solid state peltier cooled detector. Beam aperture was controlled using tube divergence and anti-scatter slits of 2 and 4 mm

35 and detector anti-scatter and receiving slits of 0.5 and 0.3 mm width. Data were collected from 2° to 30° two-theta using a step scan of 0.03°/point with a one second/point

counting time. The samples were hand ground using a pestle and mortar and packed into an aluminum sample tray with a 12mm (diam.) x 0.5mm cavity.

DSC

- 5 Measurements of differential scanning calorimetry were obtained on a Mettler TA 4000 thermal analysis system. Approximately 8.5 mg samples were accurately weighed into a DSC pan. The pans were hermetically sealed and a pinhole was punched into the pan lid. The use of the pinhole allows for
10 pressure release, but still assures that the thermal reactions proceed under controlled conditions. The samples were introduced into the DSC oven and then heated at a rate of 5°C/min, up to a final temperature of 135°C.

IR Spectroscopy

- 15 IR spectra of cabergoline form I and V were obtained on a Perkin Elmer FT-IR spectrophotometer PARAGON 1000. The sample were prepared by KBr powder technique registering the spectra on reflectance.

Solid state ¹³C-NMR

- 20 Solid state ¹³C-NMR spectra were obtained on a MSL 300 Bruker instrument equipped with solid state facilities and variable temperature magic angle spinning probe. Cross polarisation experiments were performed by a decoupling field of 50 KHz and single pulse magic angle spinning experiments with
25 recycle times ranging from 10 to 100 records.

The x-ray powder diffraction pattern for Form I (Figure 1) shows a crystalline structure with useful distinctive peaks at approximately 9.7, 10.4 and 24.8 deg 2-theta.

- The DSC curve of Form I (Figure 2) exhibits a melting
30 endotherm at approximately 100°- 105°C. The integrated melting endotherm has a heat of fusion of approximately 60 J/g.

The IR spectrum of Form I is shown in Figure 3.

- The solid state ¹³C-NMR spectrum of form I is shown in figure
35 4.

These data indicate that cabergoline Form I is a crystalline polymorph easily distinguishable by XRD and solid state ¹³C-

NMR techniques. DSC and IR are other two useful techniques to characterize the polymorph. The process of the present invention for producing crystalline cabergoline Form I is characterized by crystallisation from a toluene/diethyl ether mixture. The process comprises dissolving the raw final cabergoline, obtained as an oil through the synthesis described in Eur. J. Med. Chem., 24, 421, (1989), in a suitable amount of a toluene/diethyl ether mixture, preferably about 1:1 mixture. The resultant solution is then cooled at a temperature of from -25° to -9°C, preferably at about -12°C for 17 hours. In these conditions, a toluene solvate is obtained, named Form V, that may be recovered by common procedures, for example by filtration under reduced pressure or by centrifugal filtration, followed by smoothly drying of the resultant solid. The resultant crystals of Form V are then converted into form I upon further drying. The crystals of Form I of cabergoline prepared according to the process of the present invention have preferably a polymorph purity > 95%, more preferably >98%. Toluene solvate form V is also object of the present invention. The x-ray powder diffraction pattern for Form V (Figure 5) shows a crystalline structure.

The DSC curve of solvate Form V (Figure 6) exhibits a melting endotherm at approximately 60°-65°C.

The IR spectrum of solvate Form V is shown in Figure 7. The solid state ¹³C-NMR spectrum of form V is shown in figure 8.

These data indicate that cabergoline solvate Form V is easily distinguishable by XRD, DSC and solid state ¹³C-NMR techniques. IR, combined with another analytical technique, is another method to identify the solvate.

The solvate V of this invention is a true solvate having a fixed composition of about 0.5 toluene moles per mole of cabergoline.

Example 1.

The oil obtained by purification on a chromatographic column after the final step of the synthetic path according to the

preparation described in Eur. J. Med. Chem., 24, 421, (1989) and containing 100 g of pure cabergoline was dissolved in toluene to give 243 g of a cabergoline toluene solution. The solution was introduced into a reactor pre-cooled at -12°C, and 182 g of toluene were added to give a 23.5% w/w cabergoline concentration in this solvent. After cooling again at -12°C, 362 ml of diethyl ether were added. The mixture was cooled again at -12°C and stirred at this temperature for about 17 hours. The obtained precipitate was filtered under vacuum and smoothly dried. The resultant crystal solvate form V was identified by XRD, DSC, IR and NMR, data shown in figures 5-8 respectively. Yield was about 45%(w/w) on the basis of pure cabergoline initial content.

Example 2.

The crystal solvate form V obtained in example 1 was dried at a temperature of from 40°C under vacuum to 65°C under vacuum. After drying, the resultant crystal form I was identified by XRD, DSC, IR and NMR, data shown in figures 1-4 respectively. Yield was about 40% on the basis of pure cabergoline initial content. The assayed polymorph purity was >98%.

CLAIMS

1. A process for producing cabergoline Form I, which process comprises crystallisation of the desired
5 crystalline form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals.
2. A process according to claim 1 in which the crystallisation comprises dissolving raw cabergoline in a
10 toluene/diethyl ether mixture, cooling the resulting solution, collecting the resulting solvate form V of cabergoline having the XRD powder pattern of Figure 5 and converting the solvate into cabergoline Form I by drying.
3. A process according to claim 1 or 2 in which the
15 toluene/ diethyl ether mixture is a 1:1 mixture.
4. A process according to claim 2 or 3 in which the toluene/diethyl ether mixture is cooled to a temperature of from -25° to -9°C.
5. A process according to claim 4, in which the
20 toluene/diethyl ether mixture is cooled to a temperature of about -12°C.
6. Solvate form V of cabergoline having the XRD powder pattern of Figure 5.
7. A process for producing solvate form V of cabergoline as
25 defined in claim 6, which process comprises dissolving raw cabergoline in a toluene/diethyl ether mixture, cooling the resulting solution and collecting the resulting solvate form V of cabergoline.
8. A process according to claim 9 in which the toluene/
30 diethyl ether mixture is a 1:1 mixture.
9. A process according to claim 7 or 8, in which the toluene/diethyl ether mixture is cooled to a temperature of from -25° to -12°C, and the solvate form V is collected by filtration under reduced pressure or by centrifugal
35 filtration, followed by smoothly drying the resulting solid.

FIG. 1




FIG. 2




FIG. 3






FIG. 4









FIG. 7






FIG. 8

INTERNATIONAL SEARCH REPORT

In national Application No

PCT/EP 01/03099

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D457/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>SABATINO P ET AL: "X-RAY CRYSTAL STRUCTURE AND CONFORMATIONAL ANALYSIS OF N-(3-DIMETHYLAMINOPROPYL)-N-(ETHYLAMINOCARBONYL)-6-(2-PROPENYL)ERGOLINE-8BETA-CARBOXAMIDE (CABERGOLINE): COMPARISON WITH BROMOCRIPTINE AND LISURIDE AND A HYPOTHESIS FOR ITS HIGH DOPAMINERGIC ACTIVITY"</p> <p>FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT,</p> <p>vol. 50, no. 3, 1995, pages 175-178, XP001000162</p> <p>ISSN: 0014-827X</p> <p>cited in the application</p> <p>Page 175, Experimental Section: "crystals of Cabergoline were grown from ethylic ether".</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-9



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

7 August 2001

Date of mailing of the international search report

17/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Weisbrod, T

INTERNATIONAL SEARCH REPORT

International Application No

P EP 01/03099

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BRAMBILLA E ET AL: "SYNTHESIS AND NIDATION INHIBITORY ACTIVITY OF A NEW CLASS OF ERGOLINE DERIVATIVES SYNTHESE ET ACTIVITE INHIBITRICE SUR LA NIDATION D'UNE NOUVELLE CLASSE DE DERIVES DE L'ERGOLINE" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.CHIMICA THERAPEUTICA, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 24, 1989, pages 421-426, XP001005360 ISSN: 0223-5234 cited in the application Page 424, Exp. Protocol for compound IX: "after cryst. from diethyl ether, IX was obtained as a white solid, mp. 102-104 °C". -----	1-9
A	GB 2 103 603 A (FARMITALIA CARLO ERBA) 23 February 1983 (1983-02-23) cited in the application example 1 -----	1-9
A	US 4 526 892 A (SALVATI, P. ET AL.) 2 July 1985 (1985-07-02) cited in the application example 20 -----	1-9
A	US 5 382 669 A (CANDIANI, I. ET AL.) 17 January 1995 (1995-01-17) example 4 -----	1-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/03099

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2103603 A	23-02-1983	BE 894060 A	01-12-1982
		DE 3229665 A	24-02-1983
		JP 1655200 C	13-04-1992
		JP 3021030 B	20-03-1991
		JP 58038282 A	05-03-1983
US 4526892 A	02-07-1985	BG 61058 B	30-09-1996
US 5382669 A	17-01-1995	AT 180783 T	15-06-1999
		AU 653099 B	15-09-1994
		AU 3497493 A	05-10-1993
		CA 2106371 A	13-09-1993
		CN 1076196 A, B	15-09-1993
		CZ 9302715 A	13-04-1994
		DE 69325138 D	08-07-1999
		WO 9318034 A	16-09-1993
		EP 0593692 A	27-04-1994
		FI 934933 A	08-11-1993
		HU 66712 A, B	28-12-1994
		IL 104973 A	10-06-1997
		JP 6507648 T	01-09-1994
		MX 9301297 A	01-09-1993
		NO 934077 A	11-11-1993
		NZ 249115 A	27-04-1995
		PH 30138 A	21-01-1997
		RU 2118323 C	27-08-1998
		SK 140193 A	09-11-1994
		ZA 9301720 A	01-11-1993